Stem cell developer Arteriocyte has signed a research and development deal with the Army to investigate new therapies for orthopedic trauma and battlefield injuries.
Arteriocyte is already working with the U.S. Army Institute of Surgical Research (USAISR) to develop stem cell-based, point-of-care therapies for amputation prevention, burn debridement and post-surgical wound infection prevention, according to a statement from the Cleveland-based company.
Under terms of the new three-year deal, Arteriocyte would work with USAISR to explore broader use of its technologies to treat orthopedic trauma, such as limb injuries that affect battlefield-wounded soldiers.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The work will involve two Arteriocyte technologies: Magellan and NANEX. Magellan involves a bedside device that harvests and quickly concentrates stem cells and blood platelets during surgeries. The concentrated cells can then be fed back to patients to boost the body’s ability to repair itself.
The company’s NANEX technology uses stem cells to create “universal-donor” red blood cells (pdf), among other cell applications.
“These technologies have significant potential to improve outcomes for our injured personnel and assist in their healthy recovery to active duty,” said Joseph Wenke, manager of USAISR’s orthopedic extremity trauma research program.
Earlier this year, Arteriocyte received approval from the U.S. Food and Drug Administration to begin a phase 1 clinical trial that uses the Magellan technology for the treatment of critical limb ischemia.
